80 completed, 18 terminated, 12 recruiting, 10 unknown. 138 Phase 2, 22 Phase 3, 15 Phase 1.
Follow Seizures: new trials by email Literature Review of Seizures trials Research Report on Seizures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) AV078, Placebo - Tuberous Sclerosis Complex, Epilepsy | Phase 2 | Not yet recruiting | Aeovian Pharmaceuticals, Inc. | 42 | 2026-09-01 | 2026-09-29 |
| Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial Ayahuasca - Non Epileptic Seizures | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 15 | 2026-07-01 | 2026-08-05 |
| Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases Levetiracetam (Keppra) - Seizures, Primary Motor Cortex | Phase 2 | Recruiting | Ayal A. Aizer, MD | 150 | 2025-12-23 | 2026-09-08 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy | Phase 2 | Recruiting | Rapport Therapeutics Inc. | 30 | 2025-12-15 | 2026-01-23 |
| Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) Ketamine, Midazolam - Convulsive Status EPILEPTICUS | Phase 2 / Phase 3 | Recruiting | Sohag University | 668 | 2025-08-03 | 2025-08-05 |
| SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures SPN-817 - Focal Onset Seizures | Phase 2 | Enrolling by invitation | Supernus Pharmaceuticals, Inc. | 100 | 2025-07-30 | 2026-10-27 |
| Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children Ketamine, Levetiracetam, Placebo - Generalized Convulsive Status Epilepticus | Phase 2 / Phase 3 | Recruiting | Sohag University | 124 | 2025-07-02 | 2025-07-03 |
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures 30mg PRAX-628 - Focal Onset Seizure, Primary Generalized Epilepsy | Phase 2 | Recruiting | Praxis Precision Medicines | 50 | 2025-01-10 | 2025-04-03 |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures SPN-817, Placebo - Focal Onset Seizures | Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc. | 216 | 2024-12-30 | 2026-10-01 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo - Focal Seizure | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 255 | 2024-12-11 | 2026-08-10 |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy RAP-219 - Focal Onset Seizures | Phase 2 | Completed | Rapport Therapeutics Inc. | 30 | 2024-10-10 | 2026-02-05 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
| Long-term Safety and Tolerability of BHV-7000 BHV-7000 - Focal Epilepsy | Phase 2 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 660 | 2024-07-30 | 2026-05-01 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Perampanel, Placebo - Heart Arrest, Seizures | Phase 2 | Recruiting | University of California, San Francisco | 52 | 2024-05-20 | 2026-07-29 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-05-13 | 2026-08-13 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-03-14 | 2026-09-30 |
| buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia - Hypoxia-Ischemia, Brain, Heart Arrest | Phase 2 | Recruiting | University of California, San Francisco | 30 | 2023-08-07 | 2026-07-29 |
| Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) IV Ganaxolone, IV Placebo - Status Epilepticus | Phase 2 | Withdrawn | Marinus Pharmaceuticals | 2023-04-01 | 2024-05-07 |
Showing 20 of 138. Sign in to see all of them.
Epilepsy (77) · Epilepsies, Partial (18) · Status Epilepticus (18) · Drug Resistant Epilepsy (14) · Brain Diseases (7) · Epilepsy, Idiopathic Generalized (5) · Coma (4) · Heart Arrest (4) · Tuberous Sclerosis (4) · Anxiety Disorders (3) · Brain Neoplasms (3) · Epilepsy, Generalized (3) · Epilepsy, Reflex (3) · Hypoxia-Ischemia, Brain (3)
Pathological Conditions, Signs and Symptoms (138) · Signs and Symptoms (138) · Nervous System Diseases (137) · Neurologic Manifestations (137) · Central Nervous System Diseases (96) · Brain Diseases (91) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Epilepsy (12) · Cardiovascular Diseases (11) · Genetic Diseases, Inborn (11) · Neoplasms (10) · Epileptic Syndromes (9) · Nutritional and Metabolic Diseases (8) · Vascular Diseases (8)
Levetiracetam (16) · perampanel (9) · Topiramate (6) · ganaxolone (5) · Diazepam (4) · Ketamine (4) · Lacosamide (4) · Midazolam (4) · Phenobarbital (3) · Valproic Acid (3) · Benzodiazepines (2) · Carbamazepine (2) · Fish Oils (2) · Lamotrigine (2) · Lorazepam (2)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Marinus Pharmaceuticals (6) · Sohag University (6) · Eisai Inc. (5) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · Supernus Pharmaceuticals, Inc. (5) · Biohaven Therapeutics Ltd. (4) · Eisai Co., Ltd. (4) · GlaxoSmithKline (3) · Jazz Pharmaceuticals (3) · UCB BIOSCIENCES, Inc. (3) · University of Rochester (3) · AbbVie (2) · Acorda Therapeutics (2) · Children's Hospital Medical Center, Cincinnati (2)
United States (87) · Spain (21) · Australia (18) · Poland (17) · Italy (15) · Hungary (14) · France (13) · Germany (13) · Belgium (12) · United Kingdom (11) · Czechia (10) · Netherlands (9) · Canada (8) · Japan (8) · Mexico (7)
Maciej Gasior, MD, PhD (4) · Abdelrahim A Sadek, MD, PhD (3) · Christopher M DeGiorgio, MD (2) · Edilberto Amorim, MD (2) · Gretchen L Birbeck, M.D. (2) · Jacqueline French, M.D. (2) · Adrian Lacy, MD (1)
PMID 35305920, PMID 28086164, PMID 31672143, PMID 35965432, PMID 12628059, PMID 16499758, PMID 16861095, PMID 16886975, PMID 20667792, PMID 20679166, PMID 21167786, PMID 22495532, PMID 22913800, PMID 23365066, PMID 24756515, PMID 25201887, PMID 26696953, PMID 27693237, PMID 27993298, PMID 28500900, PMID 29382251, PMID 30232735, PMID 30289769, PMID 30427550, PMID 30679288, PMID 30841858, PMID 31049885, PMID 31292226, PMID 31518978, PMID 33973646, PMID 33998885, PMID 34015244, PMID 34119901, PMID 34332638, PMID 34521687, PMID 34528245, PMID 35067230, PMID 35748707, PMID 35841234, PMID 36176044, PMID 36316704, PMID 36529709, PMID 36870093, PMID 37973662, PMID 38640099, PMID 38754459, PMID 38857015, PMID 38902005, PMID 39499201, PMID 40247384
2014 (7), 2023 (4), 2017 (3), 2018 (3), 2019 (2), R01NS074409 (2), 2016 (1), 2025 (1), K23AT001933 (1), P50CA165962 (1), R01NS102176 (1), UH3NS109557 (1), UH3TR003897 (1)